Collaboration: discovery against GPCRs, ion channels and transporters 


Swedish biotech company Salipro Biotech has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Platform, which stabilises challenging G protein coupled receptor (GPCR), ion channel and transporter antigens. 

“We are excited to build on the success of our previous studies and deepen our relationship with the team at AbCellera,” said Jens Frauenfeld, CEO of Salipro Biotech. “We look forward to deploying our expertise and our platform technology to generate Salipro-stabilised antigens of challenging membrane proteins to enable AbCellera’s discovery programmes against these drug targets.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free